Incyte Co. (NASDAQ:INCY – Get Free Report) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 5,100,000 shares, a decrease of 13.1% from the December 15th total of 5,870,000 shares. Based on an average trading volume of 1,960,000 shares, the short-interest ratio is presently 2.6 days. Currently, 2.7% of the company’s stock are sold short.
Incyte Stock Down 0.7 %
NASDAQ INCY traded down $0.54 during trading hours on Friday, hitting $71.93. The company had a trading volume of 1,004,226 shares, compared to its average volume of 1,542,123. The company has a market capitalization of $13.86 billion, a price-to-earnings ratio of 513.82, a P/E/G ratio of 0.51 and a beta of 0.71. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.87 and a quick ratio of 1.82. Incyte has a fifty-two week low of $50.35 and a fifty-two week high of $83.95. The firm’s 50 day moving average is $72.36 and its 200 day moving average is $67.98.
Incyte (NASDAQ:INCY – Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing the consensus estimate of $1.19 by ($0.12). The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.08 billion. Incyte had a negative return on equity of 0.63% and a net margin of 0.80%. Incyte’s revenue was up 23.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.91 earnings per share. Sell-side analysts anticipate that Incyte will post 0.4 earnings per share for the current fiscal year.
Insider Buying and Selling
Institutional Investors Weigh In On Incyte
Several large investors have recently made changes to their positions in the company. Pacer Advisors Inc. boosted its stake in shares of Incyte by 17,460.4% during the 2nd quarter. Pacer Advisors Inc. now owns 2,692,182 shares of the biopharmaceutical company’s stock worth $163,200,000 after acquiring an additional 2,676,851 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Incyte in the third quarter valued at approximately $156,611,000. Mizuho Securities USA LLC increased its position in Incyte by 13,814.7% during the third quarter. Mizuho Securities USA LLC now owns 2,000,100 shares of the biopharmaceutical company’s stock worth $132,207,000 after buying an additional 1,985,726 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Incyte by 70.5% in the 2nd quarter. AQR Capital Management LLC now owns 2,661,758 shares of the biopharmaceutical company’s stock worth $159,905,000 after purchasing an additional 1,101,041 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky boosted its holdings in shares of Incyte by 2,486.8% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 394,646 shares of the biopharmaceutical company’s stock worth $23,923,000 after buying an additional 379,390 shares during the period. Institutional investors and hedge funds own 96.97% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on INCY shares. JPMorgan Chase & Co. increased their price objective on Incyte from $65.00 to $71.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. StockNews.com lowered shares of Incyte from a “strong-buy” rating to a “buy” rating in a report on Friday, December 13th. Royal Bank of Canada upped their target price on Incyte from $72.00 to $80.00 and gave the company a “sector perform” rating in a research note on Thursday, November 14th. JMP Securities reissued a “market perform” rating on shares of Incyte in a research report on Tuesday, January 14th. Finally, Oppenheimer boosted their target price on shares of Incyte from $81.00 to $82.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Incyte presently has a consensus rating of “Hold” and an average price target of $76.29.
Read Our Latest Stock Report on Incyte
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Read More
- Five stocks we like better than Incyte
- How to Effectively Use the MarketBeat Ratings Screener
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- How to Invest in Small Cap StocksĀ
- Oilfield Leader SLB: An AI Name You Need to Know
- The 3 Best Retail Stocks to Shop for in August
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.